Tata Memorial Hospital Conference Highlights New Cancer Treatments, Immunotherapy And Genetic Testing For Women

Mumbai: A two-day conference at Tata Memorial Hospital, themed "Gynaecological Cancers: Evidence meets Practice," is exploring the latest advancements in treating cervical, ovarian, and uterine cancers. The conference, taking place from October 10-11, focuses on immunotherapy, targeted medicines, and advanced radiotherapy as potential treatment options.

According to GLOBOCAN 2024 estimates, there were over 1.5 lakh new cases of cervical, ovarian, and uterine corpus cancers in India in 2024. This emphasizes the importance of timely diagnosis and appropriate treatment. Molecular and genetic testing plays a crucial role in guiding treatment decisions, helping doctors understand tumour characteristics and identify patients who may benefit from specific therapies.

The conference features experts from India and abroad, including Prof Jonathan Ledermann of University College London, Prof Denis Querleu of the University of Toulouse, and Prof Cyrus Chargari of Sorbonne University. They will discuss various aspects of gynaecological cancers, such as PARP inhibitors for ovarian cancer, immunotherapy for cervical cancer, and molecular classification for endometrial cancer.

Other topics covered include fertility preservation, survivorship, and quality of life after treatment. Pre-conference workshops covered advanced pelvic surgery, radiotherapy, brachytherapy, and the use of artificial intelligence in oncology. The goal is to translate scientific advancements into evidence-based treatment decisions, ultimately improving patient outcomes.